Dataset Information

Characterisation of cancer stem cells and the renin-angiotensin system in colon adenocarcinoma

ABSTRACT: LC-MS/MS Proteomics was performed to determine proteomic differences between colon adenocarcinoma (CA) tissues and patient-matched normal colon tissues, CA-derived primary cell lines and NC-derived primary cells, and between LGCA tissues and cell lines and HGCA tissues and cell lines. Biological processes which may link the renin-angiotensin system and CA were investigated, revealing enrichment of various signalling pathways that may play roles in CA onset and progression directly or via the renin-angiotensin system.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Colon

DISEASE(S): Colon Cancer

SUBMITTER: Danyl Mclauchlan

LAB HEAD: Lifeng Peng

PROVIDER: PXD024449 | Pride | 2022-08-12

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	Cells_requent_Nov_20th_2020.mzML	Mzml
	Cells_requent_Nov_20th_2020.mzid.gz	Mzid
	Matt_HG1_Cells_20ug.raw	Raw
	Matt_HG1_Cells_20ug_20191205221126.raw	Raw
	Matt_HG1_Cells_20ug_20191206150443.raw	Raw

Items per page:

1 - 5 of 79

Publications

Proteomic analysis of low- and high-grade human colon adenocarcinoma tissues and tissue-derived primary cell lines reveals unique biological functions of tumours and new protein biomarker candidates.

Munro Matthew J MJ Wickremesekera Susrutha K SK Tan Swee T ST Peng Lifeng L

Clinical proteomics 20220716 1

<h4>Background</h4>Colon cancer is the third most common cancer and second highest cause of cancer deaths worldwide. The aim of the study was to find new biomarkers for diagnosis, prognosis and therapeutic drug targets for this disease.<h4>Methods</h4>Four low-grade and four high-grade human colon adenocarcinoma tumours with patient-matched normal colon tissues were analysed. Additionally, tissue-derived primary cell lines were established from each tumour tissue. The cell lines were validated u ...[more]

PMID: 35842572

Similar Datasets

Project description:We sought to test whether vaccine-induced immune responses could protect rhesus macaques (RMs) against upfront heterologous challenges with an R5 simian-human immunodeficiency virus, SHIV-2873Nip. We immunized the RMs with recombinant Env proteins heterologous to the challenge virus. For induction of immune responses against Gag, Tat, and Nef, we explored a strategy of immunization with overlapping synthetic peptides (OSP). The immune responses against Gag and Tat were finally boosted with recombinant proteins. The vaccinees and a group of ten control animals were given five low-dose intrarectal (i.r.) challenges with SHIV-2873Nip. All controls and seven out of eight vaccinees became systemically infected; there was no significant difference in viremia levels of vaccinees vs. controls. Prevention of viremia was observed in one vaccinee which showed strong boosting of virus-specific cellular immunity during virus exposures. The protected animal showed no challenge virus-specific neutralizing antibodies in the TZM-bl or A3R5 cell-based assays and had low level ADCC activity after the virus exposures. Microarray data strongly supported a role for cellular immunity in the protected animal. Our study represents a case of protection against heterologous tier 2 SHIV-C by vaccine-induced, virus-specific cellular immune responses. For the protected RM, blood was collected before vaccination, on the day of first virus exposure and six weeks after last virus challenge. Lymph node and rectal pinch biopsies were performed before vaccination and six weeks after last virus challenge. Blood was collected in tempus tubes and processed immediately according to the manufacturer’s instructions and stored at -80C. The biopsy specimens were cut into small pieces and immediately placed into RNAlater solution (Qiagen, Valencia, CA) and also stored at -80C. Total RNA from blood, lymph node and rectal biopsies was extracted using RNAeasy extraction kits (Qiagen, Valencia, CA). cDNA labeling, hybridization, staining and scanning were performed according to the manufacturer’s instructions (Affymetrix, Santa Clara, CA) for rhesus gene expression arrays.